Guvenc et al. reported that LLP-3 treatment disrupted the survivin–Ran protein complex, eliminated the Ran effector molecule TPX2, and abolished the growth of patient-derived glioblastoma multiforme (GBM) in vitro and in vivo [148]. This evidence concerns the gene TPX2 and glioblastoma.